NLRP3 and small cell lung carcinoma: RRx-001 (3) is a minimally toxic Nod-like receptor family pyrin domain containing 3 (NLRP3) inhibitor and nitric oxide (NO) donor with chemoradiosensitizing, vascular normalizing, and macrophage repolarizing properties (4, 5) in a Phase 3 trial called REPLATINUM (NCT03699956) for the treatment of small cell lung cancer (SCLC).